164 related articles for article (PubMed ID: 33612776)
1. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
3. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
5. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.
Lim SK; Othman R; Yusof R; Heh CH
Chem Biol Drug Des; 2021 Jan; 97(1):28-40. PubMed ID: 32657543
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.
Lee H; Zhu T; Patel K; Zhang YY; Truong L; Hevener KE; Gatuz JL; Subramanya G; Jeong HY; Uprichard SL; Johnson ME
PLoS One; 2013; 8(10):e75144. PubMed ID: 24130685
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
8. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
[TBL] [Abstract][Full Text] [Related]
9. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
[TBL] [Abstract][Full Text] [Related]
13. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
14. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
16. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
17. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
Qin Z; Wang M; Yan A
Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
[TBL] [Abstract][Full Text] [Related]
18. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
19.
Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the inhibitory effect of eight compounds from
Wei Y; Yang J; Kishore Sakharkar M; Wang X; Liu Q; Du J; Zhang JJ
Nat Prod Res; 2020 Jun; 34(11):1607-1610. PubMed ID: 30449158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
